97010 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Hormones Secretins
FUSION PROTEIN HAVING TRIPLE ACTIVITY AND USE THEREOF
#2MODIFIED GIP PEPTIDE ANALOGUES
#3Optimized GIP Peptide Analogues
#4GLP-1/GIP DUAL-TARGETED POLYPEPTIDE AND FUSION PROTEIN AND APPLICATIONS THEREOF
#5FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES
#6PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST
#7PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST
#8TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS
#9FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES
#10GIP RECEPTOR AGONIST AND USE THEREOF
#11Fusion proteins for the treatment of cardiometabolic diseases
#12GIP DERIVATIVES AND USES THEREOF
#13COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE
#14FUSION PROTEIN FOR TREATING METABOLIC DISEASES, AND PREPARATION METHOD AND USE THEREOF
#15Optimized GIP Peptide Analogues
#16GLP-1, GIP AND GLUCAGON RECEPTOR TRIPLE AGONISTS
#17GIP/GLP1 CO-AGONIST COMPOUNDS
#18Modified GIP peptide analogues
#19PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST
#20Modified GIP peptide analogues
#21GIP derivatives and uses thereof
#22LONG-ACTING PROTEIN CONJUGATES FOR BRAIN TARGETING, A PREPARATION METHOD THEREOF, AND A COMPOSITION COMPRISING THE SAME
#23Peptide dual agonists of GIPR and GLP2R
#24LONG ACTING PROTEINS AND PEPTIDES AND METHODS OF MAKING AND USING THE SAME
#25Protein and protein conjugate for diabetes treatment, and applications thereof
#26Peptide dual agonists of GIPR and GLP2R
#27GIP derivatives and uses thereof
#28GIP-GLP-1 dual agonist compounds and methods
#29SOLID PHASE PEPTIDE SYNTHESIS
#30Cysteine analogs of exendin-4
#31STABILIZED BIOACTIVE PEPTIDES AND METHODS OF IDENTIFICATION, SYNTHESIS, AND USE
#32Protein and protein conjugate for diabetes treatment, and applications thereof
#33Solid phase peptide synthesis
#34Stabilizied bioactive peptides and methods of identification, synthesis and use
#35LONG ACTING PROTEINS AND PEPTIDES AND METHODS OF MAKING AND USING THE SAME
#36GIP-GLP-1 dual agonist compounds and methods
#37GIP AND GLP-1 RECEPTOR DUAL-AGONISTS FOR THE TREATMENT OF DIABETES
#38GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE ANALOGUES
#39ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE
#40Protein and protein conjugate for diabetes treatment, and applications thereof
#41N- and C-terminal substituted antagonistic analogs of GH-RH
#42Stabilized bioactive peptides and methods of identification, synthesis, and use
#43N- and C- terminal substituted antagonistic analogs of GH-RH
#44Stabilized bioactive peptides and methods of identification, synthesis, and use
#45METHOD FOR INTRODUCING DOTA
#46Glucose-dependent insulinotropic polypeptide analogues
#47Analogues of glucose-dependent insulinotropic polypeptide
#48Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
#49Methods of making proteins and peptides containing a single free cysteine
#50Stabilized bioactive peptides and methods of identification, synthesis, and use
#51Fragments of virus protein 2 or 3 of polyoma virus as vehicles for active substances
#52Methods for the production of peptide derivatives
#53Stabilized bioactive peptides and methods of identification, synthesis, and use